Cadarine 20 mg Rich Piana

Description

Cadarine 20 mg Rich Piana — This Rich Piana formulation delivers this Selective Androgen Receptor Modulator (SARM) provides targeted muscle and bone tissue activation with reduced androgenic side effects compared to traditional anabolic steroids. This formulation is dosed at 20 mg per unit.

Key Benefits

• PPARδ agonist — technically NOT a SARM (no AR binding)
• Dramatic endurance enhancement — marathon-level cardio improvement
• Fatty-acid oxidation up; does not suppress HPTA
• No PCT required
• Cancer concerns from rodent studies at 20× human dose — decide with open eyes
• Each unit dosed at 20 mg — see Recommended Dosage below for protocol-specific intake

How It Works

GW-501516, PPARδ (peroxisome proliferator-activated receptor delta) agonist. Mechanism unrelated to SARMs despite market grouping — does not touch AR. Upregulates fatty-acid oxidation, mitochondrial biogenesis, and muscle fibre-type remodeling.

Pharmacokinetics

Plasma half-life approximately 16–24 hours. Once-daily dosing. Steady-state 5 days.

Potential Side Effects

Clean for HPTA, liver, and lipids at research doses. Rodent carcinogenicity studies at supraphysiological doses (20× human equivalent) — interpret with context. No recommended human use outside research framing.

Cycle & Stacking Guide

Stacks with SARMs for recomp, or with AAS cycles for cardio support on compounds that hurt endurance (tren, trenbolone especially). Standalone during cutting phases.

Manufacturer Notes

Rich Piana is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.